BACKGROUND: Initial assessment of dyspepsia often includes noninvasive testing for Helicobacter pylori infection. Commercially available tests vary widely in cost and accuracy. Although there is extensive literature on the cost-effectiveness of H. pylori treatment, there is little information comparing the cost-effectiveness of various currently used, noninvasive testing strategies. METHODS: A Markov simulation was used to calculate cost per symptom-free year and cost per correct diagnosis. Uncertainty in outcomes was estimated using probabilistic sensitivity analysis. RESULTS: Under the baseline assumptions, cost per symptom-free year was $122 for empiric proton pump inhibitor (PPI) trial, and costs for the noninvasive test strategies ranged from $123 (stool antigen) to $129 (IgG/IgA combined serology). Confidence intervals had significant overlap. CONCLUSIONS: Under our assumptions for how testing for H. pylori infection is employed in United States medical practice, the available noninvasive tests all have similar cost-effectiveness between one another as well as with empiric PPI trial.
BACKGROUND: Initial assessment of dyspepsia often includes noninvasive testing for Helicobacter pylori infection. Commercially available tests vary widely in cost and accuracy. Although there is extensive literature on the cost-effectiveness of H. pylori treatment, there is little information comparing the cost-effectiveness of various currently used, noninvasive testing strategies. METHODS: A Markov simulation was used to calculate cost per symptom-free year and cost per correct diagnosis. Uncertainty in outcomes was estimated using probabilistic sensitivity analysis. RESULTS: Under the baseline assumptions, cost per symptom-free year was $122 for empiric proton pump inhibitor (PPI) trial, and costs for the noninvasive test strategies ranged from $123 (stool antigen) to $129 (IgG/IgA combined serology). Confidence intervals had significant overlap. CONCLUSIONS: Under our assumptions for how testing for H. pyloriinfection is employed in United States medical practice, the available noninvasive tests all have similar cost-effectiveness between one another as well as with empiric PPI trial.
Authors: A J Shepherd; C L Williams; C P Doherty; M Hossack; T Preston; K E McColl; L T Weaver Journal: Arch Dis Child Date: 2000-09 Impact factor: 3.791
Authors: A Peretz; A On; H Koiefman; D Brodsky; N Isakovich; T Glyatman; M Paritsky Journal: Eur J Clin Microbiol Infect Dis Date: 2013-06-23 Impact factor: 3.267
Authors: Susan H Boklage; Allen W Mangel; Varun Ramamohan; Deirdre Mladsi; Tao Wang Journal: Patient Prefer Adherence Date: 2016-06-08 Impact factor: 2.711
Authors: Susan H Boklage; Allen W Mangel; Varun Ramamohan; Deirdre Mladsi; Tao Wang Journal: Patient Prefer Adherence Date: 2016-01-21 Impact factor: 2.711
Authors: Paula Rojas García; Simon van der Pol; Antoinette D I van Asselt; Maarten Postma; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló; Marino González; Fernando Antoñanzas Journal: Antibiotics (Basel) Date: 2021-01-08